<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2301256737
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2010
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        FERRIPROX 100MG/ML ORAL SOLUTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DEFERIPRONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Oral solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        547.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APOTEX" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            CHIESI FARMACEUTICIS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        V03AC02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Ferriprox is and what it is used for</strong></p><p>Pharmacotherapeutic group:<strong> </strong></p><p>Ferriprox is an iron chelator, a type of medicine that removes excess iron from the body.</p><p>Therapeutic indications:</p><p>Ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.</p><p>&nbsp;</p><p>Ferriprox in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before you take Ferriprox</strong></p><p>&nbsp;</p><p><strong>Do not take Ferriprox</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic (hypersensitive) to deferiprone or any of the other ingredients of Ferriprox. (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a history of repeated episodes of neutropenia (low white blood cell (neutrophil) count).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a history of agranulocytosis (very low white blood cell (neutrophil) count).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are pregnant or breast-feeding.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are currently taking medicines known to cause neutropenia or agranulocytosis (see &ldquo;Taking other medicines, herbal or dietary supplements&rdquo;).</p><p><strong>Take special care with Ferriprox</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the most serious side effect that may occur while taking Ferriprox is a very low white blood cell (neutrophil) count.</p><p>This condition, known as severe neutropenia or agranulocytosis, has occurred in 1 to 2 out of 100 people who have taken Ferriprox in clinical studies. Because white blood cells help to fight infection, a low neutrophil count may place you at risk of developing a serious and potentially life threatening infection. To monitor for neutropenia, your doctor will ask you to have a blood test (to check your white blood cell count) performed regularly, as frequently as every week, while you are being treated with Ferriprox. It is very important for you to keep all of these appointments. Report immediately to your doctor any symptoms of infection such as fever, sore throat or flu like symptoms.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are HIV positive or if your liver or kidney function is severely impaired, your doctor may recommend additional tests.</p><p>&nbsp;</p><p>Your doctor will also ask you to come in for tests to monitor body iron load. In addition, he or she might ask you to undergo liver biopsies.</p><p>&nbsp;</p><p><strong>Taking other medicines, herbal or dietary supplements</strong></p><p>Do not take medicines known to cause neutropenia or agranulocytosis (see &ldquo;Do not take Ferriprox&rdquo;).</p><p>&nbsp;</p><p>Do not take aluminium‑based antacids at the same time as taking Ferriprox.</p><p>&nbsp;</p><p>Please consult with your doctor or pharmacist before taking vitamin&nbsp;C with Ferriprox.</p><p>&nbsp;</p><p>Please tell your doctor, health care provider or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Do not take this medicine if you are pregnant or if you are trying to become pregnant. This medicine could seriously harm your baby. You must use effective contraception while you are taking Ferriprox and for 6&nbsp;months after your last dose if female and 3&nbsp;months after your last dose if male. &nbsp;Ask your doctor which method is best for you. If you become pregnant while taking Ferriprox, stop taking the medicine immediately and tell your doctor.</p><p>&nbsp;</p><p>Do not use Ferriprox if you are breast-feeding.</p><p>&nbsp;</p><p>Ask your doctor, health care provider or pharmacist for advice before taking any medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Not relevant.</p><p>&nbsp;</p><p><strong>Important information about some of the ingredients of Ferriprox 100 mg/ml oral solution</strong></p><p>Contains sunset yellow (E110), a colouring agent which may cause allergic reactions.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take Ferriprox</strong></p><p>Always take Ferriprox exactly as your doctor or health care provider has told you. You should check with your doctor, health care provider or pharmacist if you are not sure. The amount of Ferriprox that you take will depend on your weight. The usual dose is 25&nbsp;mg/kg, 3 times per day, orally, for a total daily dose of 75&nbsp;mg/kg. The total daily dose should not exceed 100&nbsp;mg/kg. Use the measuring cup to measure the volume prescribed by your doctor. Take your first dose in the morning. Take your second dose midday. Take your third dose in the evening. Ferriprox can be taken with or without food; however, you may find it easier to remember to take Ferriprox if you take it with your meals.</p><p>&nbsp;</p><p><strong>If you take more Ferriprox than you should</strong></p><p>If you have accidentally taken more than the prescribed dose, you should contact your doctor.</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to take Ferriprox</strong></p><p>Ferriprox will be most effective if you do not miss any doses. If you do miss one dose take it as soon as you remember and take your next dose at its regularly scheduled time. If you miss more than one dose do not take a double dose to make up for forgotten individual doses, just continue with your normal schedule. Do not change your daily dose without first talking to your doctor.</p><p>&nbsp;</p><p><strong>If you stop taking Ferriprox</strong></p><p>Do not end treatment with Ferriprox without first talking to your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side effects</strong></p><p>Like all medicines, Ferriprox can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>The most serious side effect of Ferriprox is severe neutropenia or agranulocytosis and has occurred in 1 to 2 out of 100&nbsp;people who have taken Ferriprox in clinical studies (see section 2). A low white blood cell count can be associated with a serious and potentially life‑threatening infection. Report immediately to your doctor any symptoms of infection such as: fever, sore throat or flu‑like symptoms.</p><p>&nbsp;</p><p><strong>Very common side effects</strong> (may affect more than 1 in 10 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reddish-brown discoloration of urine</p><p>&nbsp;</p><p>If you experience nausea or vomiting, it may help to take your Ferriprox with some food. Discoloured urine is a very common effect and is not harmful.</p><p>&nbsp;</p><p><strong>Common side effects</strong> (may affect up to 1 in 10 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low white blood cell count (agranulocytosis and neutropenia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in liver enzymes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fatigue</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in appetite</p><p>&nbsp;</p><p><strong>Not known</strong> (frequency cannot be estimated from the available data):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions including skin rash or hives</p><p>&nbsp;</p><p>Events of joint pain and swelling ranged from mild pain in one or more joints to severe disability. In most cases, the pain disappeared while patients continued taking Ferriprox.</p><p>&nbsp;</p><p>Neurological disorders (such as tremors, walking disorders, double vision, involuntary muscle contractions, problems with movement coordination) have been reported in children who had been voluntarily prescribed more than double the maximum recommended dose of 100&nbsp;mg/kg/day for several years and have also been observed in children with standard doses of deferiprone. The children recovered from these symptoms after Ferriprox discontinuation.</p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor, health care provider or pharmacist. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store Ferriprox</strong></p><p>Keep out of the reach and sight of children.</p><p>&nbsp;</p><p>Do not use Ferriprox after the expiry date which is stated on the carton and the label after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>After first opening use within 35 days. Do not store above 30&ordm;C. Store in the original package in order to protect from light.</p><p>&nbsp;</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Ferriprox contains</strong></p><p>The active substance is deferiprone. Each ml of oral solution contains 100&nbsp;mg deferiprone.</p><p>&nbsp;</p><p>The other ingredients are: purified water; hydroxyethylcellulose; glycerol (E422); concentrated hydrochloric acid (for pH adjustment); artificial cherry flavour; peppermint oil; sunset yellow (E110); sucralose (E955). See section 2. ʽImportant information about some of the ingredients of Ferriprox 100 mg/ml oral solutionʾ.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Ferriprox looks like and contents of the pack
Ferriprox oral solution is a clear, reddish orange coloured liquid. It is packaged in bottles of 250 ml or 500 ml.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder and Manufacturer</strong></p><p>&nbsp;</p><p><strong>Marketing Authorisation Holder</strong>:</p><p>Chiesi Farmaceutici S.p.A.</p><p>Via Palermo 26/A</p><p>43122 Parma</p><p>Italy</p><p>&nbsp;</p><p><strong>Manufacturer and Final Batch releaser </strong>:</p><p>Apotex Inc. &ndash; Richmond Hill Site,</p><p>Richmond Hill, Ontario,</p><p>L4C 5H2, Canada</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 03/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ما هو فريبروكس وفيم يُستخدم</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">المجموعة الدوائية:</p><p dir="RTL">فريبروكس هو عبارة عن خالب حديد، وهو نوع من الأدوية التي يتم استخدامها لإزالة الحديد الزائد من الجسم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">دواعي الاستخدام العلاجي:</p><p dir="RTL">يُستخدم العلاج الأحادي فريبروكس لمعالجة الحديد الزائد في الجسم لدى المرضى الذين يعانون من الثلاسيميا الكبرى وخاصة في حالة حظر أو عدم ملاءمة الدواء المستخدم حاليًا لتخليب الحديد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم وصف فريبروكس بالتزامن مع استخدام خالب آخر لدى المرضى الذين يعانون من الثلاسيميا الكبرى في حالة عدم فعالية العلاج الأحادي بأي خالب للحديد، أو عندما تكون الوقاية أو العلاج من العواقب المهددة للحياة الناتجة عن الحديد الزائد في الجسم (الحديد الزائد على القلب بشكل أساسي) يبرر التصحيح السريع أو المكثف.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>قبل تناول فريبروكس</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تتناول فريبروكس</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;إذا كانت لديك حساسية (حساسية شديدة) ضد ديفيريبرون أو أي من المكونات الأخرى في فريبروكس.&nbsp; (مدرجة في القسم 6)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ طبي لنوبات متكررة من انخفاض العدلات (انخفاض عدد خلايا الدم البيضاء (الخلايا المتعادلة)).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ طبي لندرة المحببات (انخفاض شديد في تعداد خلايا الدم البيضاء (الخلايا المتعادلة).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملًا أو تقومين بالرضاعة الطبيعية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول حاليًا أدوية معروف عنها أنها تتسبب في انخفاض العدلات أو ندرة المحببات (انظر قسم &quot;تناول أدوية أخرى أو مكملات غذائية عشبية أو غذائية&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توخَّ العناية الخاصة عند تناول فريبروكس</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التأثير الجانبي الأكثر خطورة والذي قد يحدث أثناء تناول فريبروكس هو الانخفاض الحاد في عدد خلايا الدم البيضاء (الخلايا المتعادلة).</p><p dir="RTL">هذه الحالة، والمعروفة باسم الانخفاض الحاد في العدلات أو ندرة المحببات، حدثت مع حالة إلى حالتين من بين 100 شخص تناولوا فريبروكس في الدراسات السريرية. نظرًا لأن خلايا الدم البيضاء تساعد في مكافحة العدوى، فإن انخفاض عدد العدلات (الخلايا المتعادلة) قد يعرضك لخطر الإصابة بعدوى خطيرة مهددة للحياة. لمراقبة انخفاض العدلات (الخلايا المتعادلة)، سيطلب منك طبيبك المعالج إجراء فحص دم (للتحقق من عدد كريات الدم البيضاء)، هذا الفحص سيتم إجراؤه بانتظام، على نحو شبه أسبوعي أثناء علاجك بواسطة فريبروكس. من المهم جدًّا الالتزام بجميع هذه المواعيد. أبلغ طبيبك المعالج فورًا في حالة حدوث أي أعراض للعدوى مثل الحمى أو التهاب الحلق أو أعراض تشبه أعراض الأنفلونزا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بفيروس نقص المناعة البشرية أو إذا كانت وظائف الكبد أو الكلى لديك تعاني من ضعف شديد، فقد يوصي طبيبك المعالج بإجراء اختبارات إضافية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أيضًا، سيطلب منك طبيبك المعالج إجراء فحوصات لمراقبة مقدار الحديد في الجسم. بالإضافة إلى ذلك، قد يطلب منك إجراء خزعات الكبد.</p><p dir="RTL">&nbsp;</p><p><strong>تناول أدوية أخرى أو مكملات غذائية عشبية أو غذائية</strong></p><p dir="RTL">لا تتناول الأدوية المعروف عنها أنها تتسبب في انخفاض العدلات أو ندرة المحببات (انظر قسم &quot;لا تتناول فريبروكس&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتناول مضادات الحموضة التي تعتمد على الألومنيوم بالتزامن مع تناول فريبروكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يرجى استشارة طبيبك المعالج أو الصيدلي قبل تناول فيتامين (ج) مع تناول فريبروكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يرجى إبلاغ طبيبك المعالج أو مقدم الرعاية الصحية أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها دون وصفة طبية.</p><p dir="RTL">&nbsp;</p><p><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">لا تتناولي هذا الدواء إذا كنتِ حاملًا أو تخططين لحمل. هذا الدواء يمكن أن يضر طفلك بشدة. يجب عليك إستخدام وسيلة فعالة لمنع الحمل أثناء تناول فريبروكس ولمدة 6 أشهر بعد آخر جرعة إذا كنت أنثى و3 أشهر بعد آخر جرعة إذا كنت ذكرا&quot;. &nbsp;استشر طبيبك المعالج لمعرفة أيٍّ من وسائل منع الحمل هي الأفضل لحالتك. إذا أصبحتِ حاملًا أثناء تناول فريبروكس، توقفي فورًا عن تناول الدواء وأخبري طبيبك المعالج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتناولي فريبروكس في حالة الرضاعة الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب استشارة الطبيب المعالج أو مقدم الرعاية الصحية أو الصيدلي قبل تناول أي دواء.</p><p dir="RTL">&nbsp;</p><p><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">ليست ذات صلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات مهمة حول بعض مكونات محلول فريبروكس 100 ملغ / مل للاستخدام عن طريق الفم</strong></p><p dir="RTL">يحتوي على عنصر غروب الشمس الأصفر (E110)، وهو عامل تلوين قد يسبب ردود فعل تحسسيّة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>كيفية تناول فريبروكس</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">احرص دائمًا على تناول فريبروكس تمامًا كما أخبرك طبيبك المعالج أو مقدم الرعاية الصحية. في حالة عدم التأكد، يجب عليك مراجعة طبيبك المعالج أو مقدم الرعاية الصحية أو الصيدلي. تعتمد كمية فريبروكس التي تتناولها على وزنك. الجرعة الاعتيادية هي 25 ملغ/كلغ، 3 مرات يوميًّا عن طريق الفم، لجرعة يومية إجمالية قدرها 75 ملغ/كلغ. يجب ألا تتجاوز الجرعة اليومية الإجمالية 100 ملغ/كلغ. استخدم كوب القياس لمعايرة الجرعة المحددة من قبل طبيبك. تناول جرعتك الأولى في الصباح. تناول جرعتك الثانية في منتصف النهار. تناول جرعتك الثالثة في المساء. يمكن تناول فريبروكس مع أو بدون الطعام؛ ومع ذلك، قد تجد أنه من السهل عليك تذكر تناول جرعة فريبروكس أثناء تناول وجبتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت جرعة من فريبروكس أكثر مما ينبغي</strong></p><p dir="RTL">إذا تناولت عن طريق الخطأ جرعة من الدواء أكثر من الجرعة الموصوفة لك، فيجب عليك أن تتصل بطبيبك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا نسيت أن تتناول فريبروكس</strong></p><p dir="RTL">سيكون فيريبروكس أكثر فاعلية إذا لم تفوِّت أي جرعات. إذا فاتك تناول جرعة واحدة، فتناولها بمجرد تذكرك ثم تناول الجرعة التالية في الوقت المحدد لها بانتظام. إذا فاتتك أكثر من جرعة واحدة، فلا تتناول جرعة مضاعفة للتعويض عن الجرعات الفردية المنسية، فقط استمر في جدولك الطبيعي. لا تغير الجرعة اليومية دون التحدث مع طبيبك المعالج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول فريبروكس</strong></p><p dir="RTL">لا توقف العلاج باستخدام فريبروكس دون التحدث إلى طبيبك المعالج.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>4.&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;الآثار الجانبية المحتملة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">كما هو الحال مع جميع الأدوية، يمكن أن يسبب فريبروكس آثارًا جانبية، على الرغم من عدم حدوثها لكل المرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">التأثير الجانبي الأكثر خطورة لفريبروكس هو الانخفاض الحاد في تعداد العدلات أو ندرة المحببات وقد حدث ذلك بنسبة حالة إلى حالتين مرضيتين من بين 100 شخص ممن يتناولون فريبروكس في التجارب السريرية (انظر القسم <strong>2</strong>). يمكن أن يترافق انخفاض عدد خلايا الدم البيضاء مع حدوث عدوى خطيرة قد تهدد الحياة. أبلغ طبيبك المعالج فورًا عن أي أعراض للعدوى مثل: الحمى والتهاب الحلق أو أعراض الإنفلونزا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة جدًّا</strong> (قد تؤثر على أكثر من 1 من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجع البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلوُّن البول إلى لون يميل إلى الاحمرار/البني</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعاني من الغثيان أو القيء، فقد يكون من المفيد تناول فريبروكس مع بعض الطعام. . تلون البول هو أثر شائع جدًّا وغير ضار.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة</strong> (قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء (ندرة المحببات وانخفاض العدلات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة أنزيمات الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في الشهية</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية غير معروفة</strong><strong> (لا يمكن تقدير التكرار من البيانات المتاحة)</strong>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل تحسسية (حساسية) بما في ذلك الطفح الجلدي أو خلايا النحل (البثور)</p><p dir="RTL">&nbsp;</p><p dir="RTL">تراوحت حالات ألم وتورم المفاصل من ألم خفيف في واحد أو أكثر من المفاصل إلى إعاقة شديدة. في معظم الحالات اختفى الألم مع استمرار المرضى في تناول فريبروكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن اضطرابات عصبية (مثل: الارتجاف، اضطرابات المشي، الرؤية المزدوجة، تقلصات العضلات اللاإرادية، مشاكل تنسيق الحركة) لدى الأطفال الذين وُصفت لهم طواعية جرعة أكثر من ضعف الجرعة القصوى الموصى بها 100 ملغ/كلغ يوميًّا لعدة سنوات، وقد لوحظت هذه الاضطرابات أيضا لدى الأطفال ممن يتناولون جرعات قياسية من <strong>&nbsp;</strong>ديفيريبرون. تعافى الأطفال من هذه الأعراض بعد وقف فريبروكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالة تعرضك لأي آثار جانبية، تحدَّث على الفور مع طبيبك المعالج أو مقدم الرعاية الصحية أو الصيدلي. يتضمن ذلك أي آثار جانبية محتملة غير مدرجة في هذه النشرة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>كيفية تخزين فريبروكس</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يحفظ بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ﻻ يستخدم فريبروكس ﺑﻌد ﺗﺎرﯾﺦ اﻧﺗﮭﺎء اﻟﺻﻼﺣﯾﺔ اﻟﻣذﮐور ﻋﻟﯽ العلبة اﻟﮐرﺗون والملصق بعد كلمة EXP. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد فتح العبوة للمرة الأولى، يُستخدم الدواء في غضون 35 يومًا. يحفظ في درجة حرارة لا تتعدّى 30 درجة مئوية. يُخزن داخل العبوة الأصلية من أجل الحفاظ على المستحضر من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عدم التخلص من الأدوية عن طريق الصرف الصحي والنفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد هناك حاجة لها. هذه الإجراءات من شأنها حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما الذي يحتوي عليه فريبروكس</strong></p><p dir="RTL">المادة الفعالة هي ديفيريبرون. كل مل من المحلول الفموي يحتوي على 100 ملغ من مادة ديفيريبرون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى: ماء مقطر؛ &nbsp;سيليلوز هيدروكسي إيثايل؛ الغليسرول (E422)؛ حمض الهيدروكلوريك المركّز (من أجل تعديل درجة الحموضة)؛ نكهة الكرز الاصطناعية؛ زيت النعناع؛ عنصر غروب الشمس الأصفر (E110)؛ سكرالوز (E955). &nbsp;أنظر قسم 2 &quot; معلومات مهمة حول بعض مكونات محلول فريبروكس 100 ملغ / مل للاستخدام عن طريق الفم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو فيريبروكس وما هي محتويات العبوة</strong></p><p dir="RTL">محلول فريبروكس الفموي هو سائل شفاف برتقالي اللون يميل إلى الأحمر. يتم تعبئته في زجاجات سعة 250 مل أو 500 مل.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك رخصة التسويق والشركة المصنعة</p><p dir="RTL">مالك رخصة التسويق :</p><p dir="RTL">Chiesi Farmaceutici S.p.A.</p><p dir="RTL">Via Palermo 26/A</p><p dir="RTL">43122 Parma</p><p dir="RTL">إيطاليا</p><p dir="RTL">&nbsp;</p><p dir="RTL">الشركة المصنعة والمسؤولة عن تحرير الصنف:</p><p dir="RTL">Apotex Inc. &ndash; Richmond Hill Site,</p><p dir="RTL">Richmond Hill, Ontario,</p><p dir="RTL">, L4C 5H2</p><p dir="RTL">كندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت الموافقة على هذه النشرة آخر مرة في 2022/03
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Ferriprox 100 mg/ml oral solution

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                

Each ml of oral solution contains 100 mg deferiprone (25 g deferiprone in 250 ml and 50 g deferiprone in 500 ml).

Excipient with known effect
Each ml of oral solution contains 0.4 mg sunset yellow (E110).
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3.	Pharmaceutical form

Oral solution.

Clear, reddish orange-coloured liquid.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.</p><p>&nbsp;</p><p>Ferriprox in combination with another chelator (see section 4.4) is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Deferiprone therapy should be initiated and maintained by a physician experienced in the treatment of patients with thalassaemia.</p><p>&nbsp;</p><p><u>Posology</u></p><p>Deferiprone is usually given as 25&nbsp;mg/kg body weight, orally, three times a day for a total daily dose of 75&nbsp;mg/kg body weight. Dose per kilogram body weight should be calculated to the nearest 2.5&nbsp;ml. See table below for recommended doses for body weights at 10&nbsp;kg increments.</p><p>&nbsp;</p><p><em>Dose table</em></p><p>To obtain a dose of about 75&nbsp;mg/kg/day, use the volume of oral solution suggested in the following table for the body weight of the patient. Sample body weights at 10&nbsp;kg increments are listed.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Body weight</strong></p><p><strong>(kg)</strong></p></td><td><p><strong>Total daily dose</strong></p><p><strong>(mg)</strong></p></td><td><p><strong>Dose</strong></p><p><strong>(mg, three times/day)</strong></p></td><td><p><strong>ml of oral solution</strong></p><p><strong>(three times/day)</strong></p></td></tr><tr><td><p>20</p></td><td><p>1500</p></td><td><p>500</p></td><td><p>5.0</p></td></tr><tr><td><p>30</p></td><td><p>2250</p></td><td><p>750</p></td><td><p>7.5</p></td></tr><tr><td><p>40</p></td><td><p>3000</p></td><td><p>1000</p></td><td><p>10.0</p></td></tr><tr><td><p>50</p></td><td><p>3750</p></td><td><p>1250</p></td><td><p>12.5</p></td></tr><tr><td><p>60</p></td><td><p>4500</p></td><td><p>1500</p></td><td><p>15.0</p></td></tr><tr><td><p>70</p></td><td><p>5250</p></td><td><p>1750</p></td><td><p>17.5</p></td></tr><tr><td><p>80</p></td><td><p>6000</p></td><td><p>2000</p></td><td><p>20.0</p></td></tr><tr><td><p>90</p></td><td><p>6750</p></td><td><p>2250</p></td><td><p>22.5</p></td></tr></tbody></table><p>&nbsp;</p><p>A total daily dose above 100&nbsp;mg/kg body weight is not recommended because of the potentially increased risk of adverse reactions (see sections 4.4, 4.8, and 4.9).</p><p>&nbsp;</p><p><em>Dose adjustment</em></p><p>The effect of Ferriprox in decreasing the body iron is directly influenced by the dose and the degree of iron overload. After starting Ferriprox therapy, it is recommended that serum ferritin concentrations, or other indicators of body iron load, be monitored every two to three months to assess the long-term effectiveness of the chelation regimen in controlling the body iron load. Dose adjustments should be tailored to the individual patient&rsquo;s response and therapeutic goals (maintenance or reduction of body iron burden). Interruption of therapy with deferiprone should be considered if serum ferritin falls below 500&nbsp;mg/l.</p><p>&nbsp;</p><p><em>Dose adjustments when used with other iron chelators</em></p><p>In patients for whom monotherapy is inadequate, Ferriprox may be used with deferoxamine at the standard dose (75 mg/kg/day) but should not exceed 100 mg/kg/day.</p><p>&nbsp;</p><p>In the case of iron-induced heart failure, Ferriprox at 75-100&nbsp;mg/kg/day should be added to deferoxamine therapy. The product information of deferoxamine should be consulted.</p><p>&nbsp;</p><p>Concurrent use of iron chelators is not recommended in patients whose serum ferritin falls below 500&nbsp;&micro;g/l due to the risk of excessive iron removal.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>There are limited data available on the use of deferiprone in children between 6 and 10 years of age, and no data on deferiprone use in children under 6 years of age.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Dose adjustment is not required in patients with mild, moderate, or severe renal impairment (see section 5.2). The safety and pharmacokinetics of Ferriprox in patients with end stage renal disease are unknown.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Dose adjustment is not required in patients with mildly or moderately impaired hepatic function (see section 5.2). The safety and pharmacokinetics of Ferriprox in patients with severe hepatic impairment are unknown.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>For oral use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
-	History of recurrent episodes of neutropenia.
-	History of agranulocytosis.
-	Pregnancy (see section 4.6).
-	Breast-feeding (see section 4.6).
-	Due to the unknown mechanism of deferiprone induced neutropenia, patients must not take medicinal products known to be associated with neutropenia or those that can cause agranulocytosis (see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><u>Neutropenia/Agranulocytosis</u></p><p><strong>Deferiprone has been shown to cause neutropenia, including agranulocytosis. The patient&rsquo;s neutrophil count should be monitored every week.</strong></p><p>&nbsp;</p><p>In clinical studies, weekly monitoring of the neutrophil count has been effective in identifying cases of neutropenia and agranulocytosis and those episodes resolved once therapy was withdrawn. If the patient develops an infection while on deferiprone, therapy should be interrupted and the neutrophil count monitored more frequently. Patients should be advised to report immediately to their physician any symptoms indicative of infection such as fever, sore throat or flu-like symptoms.</p></td></tr></tbody></table><p>Suggested management of cases of neutropenia is outlined below. It is recommended that such a management protocol be in place prior to initiating any patient on deferiprone treatment.</p><p>&nbsp;</p><p>Treatment with deferiprone should not be initiated if the patient is neutropenic.<strong> </strong>The risk of agranulocytosis and neutropenia is higher if the baseline absolute neutrophil count (ANC) is less than 1.5x10<sup>9</sup>/l.</p><p>&nbsp;</p><p><u>For neutropenia events (ANC &lt;&nbsp;1.5x10<sup>9</sup>/l and &gt;&nbsp;0.5x10<sup>9</sup>/l):</u></p><p>Instruct the patient to immediately discontinue deferiprone and all other medicinal products with a potential to cause neutropenia. The patient should be advised to limit contact with other individuals in order to reduce the risk of infection. Obtain a complete blood cell (CBC) count, with a white blood cell (WBC) count, corrected for the presence of nucleated red blood cells, a neutrophil count, and a platelet count immediately upon diagnosing the event and then repeat daily. It is recommended that following recovery from neutropenia, weekly CBC, WBC, neutrophil and platelet counts continue to be obtained for three consecutive weeks, to ensure that the patient recovers fully. Should any evidence of infection develop concurrently with the neutropenia, the appropriate cultures and diagnostic procedures should be performed and an appropriate therapeutic regimen instituted.</p><p>&nbsp;</p><p><u>For agranulocytosis (ANC &lt;&nbsp;0.5x10<sup>9</sup>/l):</u></p><p>Follow the guidelines above and administer appropriate therapy such as granulocyte colony stimulating factor, beginning the same day that the event is identified; administer daily until the condition resolves. Provide protective isolation and if clinically indicated, admit patient to the hospital.</p><p>&nbsp;</p><p>Limited information is available regarding rechallenge. Therefore, in the event of neutropenia, rechallenge is not recommended. In the event of agranulocytosis, rechallenge is contraindicated.</p><p>&nbsp;</p><p><u>Carcinogenicity/mutagenicity</u></p><p>In view of the genotoxicity results, a carcinogenic potential of deferiprone cannot be excluded (see section 5.3).</p><p>&nbsp;</p><p><u>Plasma Zn<sup>2+</sup> concentration</u></p><p>Monitoring of plasma Zn<sup>2+</sup> concentration, and supplementation in case of a deficiency, is recommended.</p><p>&nbsp;</p><p><u>HIV positive or other immunocompromised patients</u></p><p>No data are available on the use of deferiprone in HIV positive or in other immunocompromised patients. Given that deferiprone can be associated with neutropenia and agranulocytosis, therapy in immunocompromised patients should not be initiated unless potential benefits outweigh potential risks.</p><p>&nbsp;</p><p><u>Renal or hepatic impairment and liver fibrosis</u></p><p>There are no data available on the use of deferiprone in patients with end stage renal disease or severe hepatic impairment (see section 5.2). Caution<strong> </strong>must be exercised in patients with end stage renal disease or severe hepatic dysfunction. Renal and hepatic function should be monitored in these patient populations during deferiprone therapy. If there is a persistent increase in serum alanine aminotransferase (ALT), interruption of deferiprone therapy should be considered.</p><p>&nbsp;</p><p>In thalassaemia patients there is an association between liver fibrosis and iron overload and/or hepatitis&nbsp;C. Special care must be taken to ensure that iron chelation in patients with hepatitis&nbsp;C is optimal. In these patients careful monitoring of liver histology is recommended.</p><p>&nbsp;</p><p><u>Discoloration of urine</u></p><p>Patients should be informed that their urine may show a reddish/brown discoloration due to the excretion of the iron-deferiprone complex.</p><p>&nbsp;</p><p><u>Neurological disorders</u></p><p>Neurological disorders have been observed in children treated with more than 2.5 times the maximum recommended dose for several years but have also been observed with standard doses of deferiprone. Prescribers are reminded that the use of doses above 100&nbsp;mg/kg/day are not recommended. Deferiprone use should be discontinued if neurological disorders are observed (see sections 4.8 and 4.9).</p><p><u>&nbsp;</u></p><p><u>Combined use with other iron chelators</u></p><p>The use of combination therapy should be considered on a case-by-case basis. The response to therapy should be assessed periodically, and the occurrence of adverse events closely monitored. Fatalities and life-threatening situations (caused by agranulocytosis) have been reported with deferiprone in combination with deferoxamine. Combination therapy with deferoxamine is not recommended when monotherapy with either chelator is adequate or when serum ferritin falls below 500&nbsp;&micro;g/l. Limited data are available on the combined use of Ferriprox and deferasirox, and caution should be applied when considering the use of such combination.</p><p><strong>&nbsp;</strong></p><p><u>Excipients</u></p><p>Ferriprox oral solution contains the colouring agent sunset yellow (E110) which may cause allergic reactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Due to the unknown mechanism of deferiprone-induced neutropenia, patients must not take medicinal products known to be associated with neutropenia or those that can cause agranulocytosis (see section 4.3).</p><p>&nbsp;</p><p>Since deferiprone binds to metallic cations, the potential exists for interactions between deferiprone and trivalent cation-dependent medicinal products such as aluminium‑based antacids. Therefore, it is not recommended to concomitantly ingest aluminium‑based antacids and deferiprone.</p><p>&nbsp;</p><p>The safety of concurrent use of deferiprone and vitamin&nbsp;C has not been formally studied. Based on the reported adverse interaction that can occur between deferoxamine and vitamin&nbsp;C, caution should be used when administering deferiprone and vitamin&nbsp;C concurrently.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no adequate data from the use of deferiprone in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>It is not known whether deferiprone is excreted in human milk. No prenatal and postnatal reproductive studies have been conducted in animals. Deferiprone must not be used by breast-feeding mothers. If treatment is unavoidable, breast-feeding must be stopped (see section 4.3).</p><p>&nbsp;</p><p><u>Fertility</u></p><p>No effects on fertility or early embryonic development were noted in animals (see section 5.3).</p><p>&nbsp;</p><p><u>Women of childbearing potential/contraception in men and women</u></p><p>Due to the genotoxic potential of deferiprone (see section 5.3), women of childbearing potential should use effective contraceptive measures while being treated with Ferriprox and for 6&nbsp;months after the last dose. These women should be advised to immediately stop taking Ferriprox and tell their doctor if they become pregnant or plan to become pregnant (see section 4.3).</p><p>&nbsp;</p><p>Men are recommended to use effective contraceptive measures and to not father a child while receiving Ferriprox and for 3&nbsp;months after the last dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not relevant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most common adverse reactions reported during therapy with deferiprone in clinical studies were nausea, vomiting, abdominal pain, and chromaturia, which were reported in more than 10% of patients. The most serious adverse reaction reported in clinical studies with deferiprone was agranulocytosis, defined as an absolute neutrophil count less than 0.5 x 10<sup>9</sup>/l, which occurred in approximately 1% of patients. Less severe episodes of neutropenia were reported in approximately 5% of patients.</p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reaction frequencies: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System organ class</strong></p></td><td><p><strong>Very common</strong></p><p><strong>(&ge;1/10)</strong></p></td><td><p><strong>Common</strong></p><p><strong>(&ge;1/100 to &lt;1/10)</strong></p></td><td><p><strong>Frequency not known</strong></p></td></tr><tr><td><p>Blood and lymphatic system disorders</p></td><td><p>&nbsp;</p></td><td><p>Neutropenia</p><p>Agranulocytosis</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Immune system disorders</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Hypersensitivity reactions</p></td></tr><tr><td><p>Metabolism and nutrition disorders</p></td><td><p>&nbsp;</p></td><td><p>Increased appetite</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Nervous system disorders</p></td><td><p>&nbsp;</p></td><td><p>Headache</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Gastrointestinal disorders</p></td><td><p>Nausea</p><p>Abdominal pain</p><p>Vomiting</p></td><td><p>Diarrhoea</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Skin and subcutaneous tissue disorders</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Rash</p><p>Urticaria</p></td></tr><tr><td><p>Musculoskeletal and connective tissue disorders</p></td><td><p>&nbsp;</p></td><td><p>Arthralgia</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Renal and urinary disorders</p></td><td><p>Chromaturia</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>General disorders and administration site conditions</p></td><td><p>&nbsp;</p></td><td><p>Fatigue</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Investigations</p></td><td><p>&nbsp;</p></td><td><p>Increased liver enzymes</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>The most serious adverse reaction reported in clinical studies with deferiprone is agranulocytosis (neutrophils &lt;0.5x10<sup>9</sup>/l), with an incidence of 1.1% (0.6 cases per 100 patient‑years of treatment) (see section 4.4). The observed incidence of the less severe form of neutropenia (neutrophils &lt;1.5x10<sup>9</sup>/l) is 4.9% (2.5 cases per 100 patient‑years). This rate should be considered in the context of the underlying elevated incidence of neutropenia in thalassaemia patients, particularly in those with hypersplenism.</p><p>&nbsp;</p><p>Episodes of diarrhoea, mostly mild and transient, have been reported in patients treated with deferiprone. Gastrointestinal effects are more frequent at the beginning of therapy and resolve in most patients within a few weeks without the discontinuation of treatment. In some patients, it may be beneficial to reduce the dose of deferiprone and then scale it back up to the former dose. Arthropathy events, which ranged from mild pain in one or more joints to severe arthritis with effusion and significant disability, have also been reported in patients treated with deferiprone. Mild arthropathies are generally transient.</p><p>&nbsp;</p><p>Increased levels of serum liver enzymes have been reported in some patients taking deferiprone. In the majority of these patients, the increase was asymptomatic and transient, and returned to baseline without discontinuation or decreasing the dose of deferiprone (see section 4.4).</p><p>&nbsp;</p><p>Some patients experienced progression of fibrosis associated with an increase in iron overload or hepatitis&nbsp;C.</p><p>&nbsp;</p><p>Low plasma zinc levels have been associated with deferiprone in a minority of patients. The levels normalised with oral zinc supplementation.</p><p>&nbsp;</p><p>Neurological disorders (such as cerebellar symptoms, diplopia, lateral nystagmus, psychomotor slowdown, hand movements and axial hypotonia) have been observed in children who had been voluntarily prescribed more than 2.5 times the maximum recommended dose of 100&nbsp;mg/kg/day for several years. Episodes of hypotonia, instability, inability to walk, and hypertonia with inability of limb movement, have been reported in children in the post-marketing setting with standard doses of&nbsp;</p><p>deferiprone. The neurological disorders progressively regressed after deferiprone discontinuation (see sections 4.4 and 4.9).</p><p>&nbsp;</p><p>The safety profile of combination therapy (deferiprone and deferoxamine) observed in clinical studies, post-marketing experience or published literature was consistent with that characterized for monotherapy.</p><p>&nbsp;</p><p>Data from the pooled safety database from clinical studies (1343 patient-years exposure to Ferriprox monotherapy and 244 patient-years exposure to Ferriprox and deferoxamine) showed statistically significant (p&lt;0.05) differences in the incidence of adverse reactions based on System Organ Class for &ldquo;Cardiac disorders&quot;, &quot;Musculoskeletal and connective tissue disorders&rdquo; and &quot;Renal and urinary disorders&quot;. The incidences of &ldquo;Musculoskeletal and connective tissue disorders&rdquo; and &quot;Renal and urinary disorders&quot; were lower during combination therapy than monotherapy, whereas the incidence of &ldquo;Cardiac disorders&quot; was higher during combination therapy than monotherapy. The higher rate of &ldquo;Cardiac disorders&quot; reported during combination therapy than monotherapy was possibly due to the higher incidence of pre-existing cardiac disorders in patients who received combination therapy. Careful monitoring of cardiac events in patients on combination therapy is warranted (see section 4.4).</p><p>&nbsp;</p><p>The incidences of adverse reactions experienced by 18 children and 97 adults treated with combination therapy were not significantly different between the two age groups except in the incidence of arthropathy (11.1% in children vs. none in adults, p=0.02). Evaluation of rate of reactions per 100&nbsp;patient-years of exposure showed that only the rate of diarrhoea was significantly higher in children (11.1) than in adults (2.0, p=0.01).</p><p>&nbsp;</p><p>To report any side effect(s):</p><p><strong>&nbsp;</strong></p><p><em>Saudi Arabia:</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>The National Pharmacovigilance (NPC)</p><p>- Fax: +966-11-205-7662</p><p>- SFDA Call Center: 19999</p><p>- E-mail: npc.drug@sfda.gov.sa</p><p>- Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p><em>United Arab Emirates:</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Pharmacovigilance and Medical Device Section</p><p>Drug Department</p><p>Ministry of Health &amp; Prevention</p><p>P.O. Box 1853, Dubai</p><p>Tel: 80011111</p><p>Email: pv@mohap.gov.ae<em>&nbsp;</em></p></td></tr></tbody></table><p>&nbsp;</p><p><em>Oman:</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Department of Pharmacovigilance &amp; Drug Information</p><p>Directorate General of Pharmaceutical Affairs &amp; Drug Control</p><p>Ministry of Health, Sultanate of Oman</p><p>Tel: +968 22357687 / +968 22357686</p><p>Fax: +968 22358489</p><p>Email: pharma-vigil@moh.gov.om</p><p>Website : www.moh.gov.om</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Kuwait:</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Drug &amp; Food Control, Ministry of Health, Kuwait</p><p>Tel.: +965-24811532</p><p>Fax: +965-24811507</p><p>E-mail: Adr_reporting@moh.gov.kw</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Iraq:</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Iraqi Pharmacovigilance Center, Ministry of Health, Iraq</p><p>Tel: +964 7807820490</p><p>E-mail: iraqiphvc@moh.gov.iq</p><p>Website : www.tec-moh.com</p></td></tr></tbody></table><p><em>Other GCC States:</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No cases of acute overdose have been reported. However, neurological disorders (such as cerebellar symptoms, diplopia, lateral nystagmus, psychomotor slowdown, hand movements and axial hypotonia) have been observed in children who had been voluntarily prescribed more than 2.5 times the maximum recommended dose of 100&nbsp;mg/kg/day for several years. The neurological disorders progressively regressed after deferiprone discontinuation.</p><p>&nbsp;</p><p>In case of overdose, close clinical supervision of the patient is required.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group:<strong> </strong>All other therapeutic products, iron chelating agents, iron chelating agents, ATC code:<strong> </strong>V03AC02</p><p><strong>&nbsp;</strong></p><p><u>Mechanism of action </u></p><p>The active substance is deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one), a bidentate ligand which binds iron in a 3:1 molar ratio.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>Clinical studies have demonstrated that Ferriprox is effective in promoting iron excretion and that a dose of 25&nbsp;mg/kg three times per day can prevent the progression of iron accumulation as assessed by serum ferritin, in patients with transfusion‑dependent thalassaemia. Data from the published literature on iron balance studies in patients with thalassaemia major show that the use of Ferriprox concurrently with deferoxamine (coadministration of both chelators during the same day, either simultaneously or sequentially, e.g., Ferriprox during the day and deferoxamine during the night), promotes greater iron excretion than either medicinal product alone. Doses of Ferriprox in those studies ranged from 50 to 100&nbsp;mg/kg/day and doses of deferoxamine from 40 to 60 mg/kg/day. However, chelation therapy may not necessarily protect against iron‑induced organ damage.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>Studies LA16-0102, LA-01 and LA08-9701 compared the efficacy of Ferriprox with that of deferoxamine in controlling serum ferritin in transfusion-dependent thalassaemia patients. Ferriprox and deferoxamine were equivalent in promoting a net stabilization or reduction of body iron load, despite the continuous transfusional iron administration in those patients (no difference in proportion of patients with a negative trend in serum ferritin between the two treatment groups by regression analysis; p &gt;0.05).</p><p>A magnetic resonance imaging (MRI) method, T2*, was also used to quantify myocardial iron load. Iron overload causes concentration-dependent MRI T2* signal loss, thus, increased myocardial iron reduces myocardial MRI T2* values. Myocardial MRI T2* values of less than 20&nbsp;ms represent iron overload in the heart. An increase in MRI&nbsp;T2* on treatment indicates that iron is being removed from the heart. A positive correlation between MRI T2* values and cardiac function (as measured by Left Ventricular Ejection Fraction (LVEF)) has been documented.</p><p>&nbsp;</p><p>Study LA16-0102 compared the efficacy of Ferriprox with that of deferoxamine in decreasing cardiac iron overload and in improving cardiac function (as measured by LVEF) in transfusion-dependent thalassaemia patients. Sixty-one patients with cardiac iron overload, previously treated with deferoxamine, were randomized to continue deferoxamine (average dose 43 mg/kg/day; N=31) or to switch to Ferriprox (average dose 92 mg/kg/day N=29). Over the 12-month duration of the study, Ferriprox was superior to deferoxamine in decreasing cardiac iron load. There was an improvement in cardiac T2* of more than 3&nbsp;ms in patients treated with Ferriprox compared with a change of about 1&nbsp;ms in patients treated with deferoxamine. At the same time point, LVEF had increased from baseline by 3.07 &plusmn; 3.58 absolute units (%) in the Ferriprox group and by 0.32&nbsp;&plusmn;&nbsp;3.38&nbsp;absolute units (%) in the deferoxamine group (difference between groups; p=0.003).</p><p>&nbsp;</p><p>Study LA12-9907 compared survival, incidence of cardiac disease, and progression of cardiac disease in 129 patients with thalassaemia major treated for at least 4 years with Ferriprox (N=54) or deferoxamine (N=75). Cardiac endpoints were assessed by echocardiogram, electrocardiogram, the New York Heart Association classification and death due to cardiac disease. There was no significant difference in the percentage of patients with cardiac dysfunction at first assessment (13% for Ferriprox vs. 16% for deferoxamine). Of patients with cardiac dysfunction at first assessment, none treated with deferiprone compared with four (33%) treated with deferoxamine had worsening of their cardiac status (p=0.245). Newly diagnosed cardiac dysfunction occurred in 13 (20.6%) deferoxamine-treated patients and in 2 (4.3%) Ferriprox-treated patients who were cardiac disease-free at the first assessment (p=0.013). Overall, fewer Ferriprox-treated patients than deferoxamine-treated patients showed a worsening of cardiac dysfunction from first to last assessment (4% vs. 20%, p=0.007).</p><p>&nbsp;</p><p>Data from the published literature are consistent with the results from the company-sponsored studies, demonstrating less heart disease and/or increased survival in Ferriprox-treated patients than in those treated with deferoxamine.</p><p>&nbsp;</p><p>A randomized, placebo-controlled, double-blind study evaluated the effect of concurrent therapy with Ferriprox and deferoxamine in patients with thalassaemia major, who previously received the standard chelation monotherapy with subcutaneous deferoxamine and had mild to moderate cardiac iron loading (myocardial T2* from 8 to 20 ms). Following randomization, 32&nbsp;patients received deferoxamine (34.9&nbsp;mg/kg/day for 5 days/week) and Ferriprox (75&nbsp;mg/kg/day) and 33 patients received deferoxamine monotherapy (43.4&nbsp;mg/kg/day for 5 days/week). After one year of study therapy, patients on concurrent chelation therapy had experienced a significantly greater reduction in serum ferritin (1574 &micro;g/l to 598 &micro;g/l with concurrent therapy vs. 1379 &micro;g/l to 1146 &micro;g/l with deferoxamine monotherapy, p&lt;0.001), significantly greater reduction in myocardial iron overload, as assessed by an increase in MRI T2* (11.7 ms to 17.7 ms with concurrent therapy vs. 12.4&nbsp;ms to 15.7&nbsp;ms with deferoxamine monotherapy, p=0.02) and significantly greater reduction in liver iron concentration, also assessed by an increase in MRI T2* (4.9 ms to 10.7 ms with concurrent therapy vs. 4.2 ms to 5.0 ms with deferoxamine monotherapy, p&lt; 0.001).</p><p>&nbsp;</p><p>Study LA37-1111 was conducted to evaluate the effect of single therapeutic (33 mg/kg) and supratherapeutic (50 mg/kg) oral doses of deferiprone on the cardiac QT interval duration in healthy subjects. The maximum difference between the LS means of the therapeutic dose and placebo was 3.01&nbsp;ms (95% one-sided UCL: 5.01&nbsp;ms), and between the LS means of the supratherapeutic dose and placebo was 5.23&nbsp;ms (95% one-sided UCL: 7.19&nbsp;ms). Ferriprox was concluded to produce no significant prolongation of the QT interval.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Deferiprone is rapidly absorbed from the upper part of the gastrointestinal tract. Peak serum concentration occurs 45 to 60 minutes following a single dose in fasted patients. This may be extended to 2 hours in fed patients.</p><p>&nbsp;</p><p>Following a dose of 25&nbsp;mg/kg, lower peak serum concentrations have been detected in patients in the fed state (85 mmol/l) than in the fasting state (126 mmol/l), although there was no decrease in the amount of deferiprone absorbed when it was given with food.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Deferiprone is metabolised predominantly to a glucuronide conjugate. This metabolite lacks iron‑binding capability due to inactivation of the 3-hydroxy group of deferiprone. Peak serum concentrations of the glucuronide occur 2 to 3 hours after administration of deferiprone.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>In humans, deferiprone is eliminated mainly via the kidneys; 75% to 90% of the ingested dose is reported as being recovered in the urine in the first 24 hours, in the form of free deferiprone, the glucuronide metabolite and the iron-deferiprone complex. A variable amount of elimination via the faeces has been reported. The elimination half‑life in most patients is 2 to 3 hours.</p><p><u>&nbsp;</u></p><p><u>Renal impairment</u></p><p>An open-label, non-randomized, parallel group clinical study was conducted to evaluate the effect of impaired renal function on the safety, tolerability, and pharmacokinetics of a single 33 mg/kg oral dose of Ferriprox. Subjects were categorized into 4 groups based on estimated glomerular filtration rate (eGFR): healthy volunteers (eGFR &ge; 90 mL/min/1.73m<sup>2</sup>), mild renal impairment (eGFR 60‑89&nbsp;mL/min/1.73m<sup>2</sup>), moderate renal impairment (eGFR 30&ndash;59 mL/min/1.73m<sup>2</sup>), and severe renal impairment (eGFR 15&ndash;29 mL/min/1.73m<sup>2</sup>). Systemic exposure to deferiprone and to its metabolite deferiprone 3-<em>O</em>-glucuronide was assessed by the PK parameters C<sub>max</sub> and AUC.</p><p>&nbsp;</p><p>Regardless of the degree of renal impairment, the majority of the dose of Ferriprox was excreted in the urine over the first 24 hours as deferiprone 3-<em>O</em>-glucuronide. No significant effect of renal impairment was seen on systemic exposure to deferiprone. Systemic exposure to the inactive 3-<em>O</em>-glucuronide increased with decreasing eGFR. Based on the results of this study, no adjustment of the Ferriprox dose regimen is required in patients with impaired renal function. The safety and pharmacokinetics of Ferriprox in patients with end stage renal disease is unknown.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>An open-label, non-randomized, parallel group clinical study was conducted to evaluate the effect of impaired hepatic function on the safety, tolerability, and pharmacokinetics of a single 33 mg/kg oral dose of Ferriprox. Subjects were categorized into 3 groups based on the Child-Pugh classification score: healthy volunteers, mild hepatic impairment (Class A: 5&ndash; 6 points), and moderate hepatic impairment (Class B: 7&ndash; 9 points). Systemic exposure to deferiprone and to its metabolite deferiprone 3-<em>O</em>-glucuronide was assessed by the PK parameters C<sub>max</sub> and AUC. Deferiprone AUCs did not differ between treatment groups, but C<sub>max</sub> was decreased by 20% in mildly or moderately hepatically impaired subjects compared with healthy volunteers. Deferiprone-3-<em>O</em>-glucuronide AUC was decreased by 10% and C<sub>max</sub> by 20% in mildly and moderately impaired subjects compared with healthy volunteers. A serious adverse event of acute liver and renal injury was seen in one subject with moderate hepatic impairment. Based on the results of this study, no adjustment of the Ferriprox dose regimen is required in patients with mildly or moderately impaired hepatic function.</p><p>&nbsp;</p><p>The influence of severe hepatic impairment on the pharmacokinetics of deferiprone and deferiprone 3‑<em>O</em>-glucuronide has not been evaluated. The safety and pharmacokinetics of Ferriprox in patients with severe hepatic impairment is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non‑clinical studies have been conducted in animal species including mice, rats, rabbits, dogs and monkeys.</p><p>&nbsp;</p><p>The most common findings in non‑iron‑loaded animals at doses of 100&nbsp;mg/kg/day and above were haematologic effects such as bone marrow hypocellularity, and decreased WBC, RBC and/or platelet counts in peripheral blood.</p><p>&nbsp;</p><p>Atrophy of the thymus, lymphoid tissues, and testis, and hypertrophy of the adrenals, were reported at doses of 100&nbsp;mg/kg/day or greater in non‑iron‑loaded animals.</p><p>&nbsp;</p><p>No carcinogenicity studies in animals have been conducted with deferiprone. The genotoxic potential of deferiprone was evaluated in a set of <em>in vitro </em>and<em> in vivo </em>tests. Deferiprone did not show direct mutagenic properties; however, it did display clastogenic characteristics in <em>in vitro</em> assays and in animals.</p><p>&nbsp;</p><p>Deferiprone was teratogenic and embryotoxic in reproductive studies in non‑iron‑loaded pregnant rats and rabbits at doses at least as low as 25&nbsp;mg/kg/day. No effects on fertility or early embryonic development were noted in non-iron-loaded male and female rats that received deferiprone orally at doses of up to 75 mg/kg twice daily for 28 days (males) or 2 weeks (females) prior to mating and until termination (males) or through early gestation (females). In females, an effect on the oestrous cycle delayed time to confirmed mating at all doses tested.</p><p>&nbsp;</p><p>No prenatal and postnatal reproductive studies have been conducted in animals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Purified water</p><p>Hydroxyethylcellulose</p><p>Glycerol (E422)</p><p>Concentrated hydrochloric acid (for pH adjustment)</p><p>Artificial cherry flavour</p><p>Peppermint oil</p><p>Sunset yellow (E110)</p><p>Sucralose (E955)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
After first opening use within 35 days.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&ordm;C. Store in the original package in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Amber polyethylene terephthalate (PET) bottles with child resistant closure (polypropylene), and a graduated measuring cup (polypropylene).</p><p>&nbsp;</p><p>Each pack contains one bottle of 250&nbsp;ml or 500&nbsp;ml oral solution.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
43122 Parma
Italy

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                03/2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>